Dublin, Jan. 23, 2017 -- Research and Markets has announced the addition of the "Vascular Dementia Forecast in 13 Major Markets 2017-2027" report to their offering.
Vascular Dementia (VaD) is the second most common form of dementia after Alzheimer disease. It is also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI), and is caused by issues with blood supply to the brain, typically caused by a series of minor strokes.
This report provides the current prevalent population for Vascular Dementia across 13 Major Markets (USA, Canada, France, Germany, Italy, Spain, United Kingdom, Brazil, Japan, India, China, Republic of Korea and Russian Federation) and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team, several of the main symptoms and co-morbidities of Vascular Dementia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Vascular Dementia include:
- Stroke
- Diabetes
- Heart disease
- Sleep apnoea (linked with hypertension)
- Other dementias
Key Topics Covered:
1. Introduction
2. Cause of the Disease
3. Risk Factors & Prevention
4. Diagnosis of the Disease
5. Variation by Geography/Ethnicity
6. Disease Prognosis & Clinical Course
7. Key comorbid conditions/Features associated with the disease
8. Methodology for quantification of patient numbers
9. Top-line prevalence for Vascular Dementia
10. Features of Vascular Dementia patients
11. Significant Comorbid Conditions associated with Vascular Dementia
12. Abbreviations used in the report
13. Patient-Based Offering
14. Online Pricing Data and Platforms
15. References
16. Appendix
For more information about this report visit http://www.researchandmarkets.com/research/6nnp8k/vascular_dementia
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Central Nervous System Drugs


TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
First Western Ship Transits Strait of Hormuz Since Iran War Began
Britain Courts Anthropic Amid US Defense Department Dispute
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 



